Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK

Current Medical Research and Opinion

Volumn 22, Issue 4, 2006, Pages 663-670

  Brown, R E ^a,c   Breugelmans, J G ^b   Theodoratou, D ^a   Benard S ^b  

^a UBC Health Care Analytics Group   (United Kingdom)

^b SANOFI PASTEUR   (France)

^c UBC   (United Kingdom)

Author keywords

Burden of illness; Cervical cancer screening; Genital warts; HPV

Indexed keywords

IMIQUIMOD; PODOPHYLLIN; PODOPHYLLOTOXIN;

ARTICLE; CANCER INCIDENCE; CANCER SCREENING; COLPOSCOPY; CONDYLOMA; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; SCREENING TEST; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA;

ADULT; COLPOSCOPY; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; DIRECT SERVICE COSTS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SERVICES RESEARCH; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; STATE MEDICINE; TREATMENT OUTCOME; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

EID: 33646245429     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X99972     Document Type: Article

References (36)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide IARC CancerBase No. 5, version 2.0. Lyon: IARCPress; 2004
2. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004;2:343-7
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9
4. Kuper H, Adami H-O, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000;248:171-83
5. Melsheimer P, Kaul S, Dobeck S, et al. Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol 2003;47:124-8
6. Voglino G, Poso F, Privitera S, et al. The role of human papillomavirus in cyto-histological practice: distribution and prevalence of high-risk strains (16, 18, 31, 33, and 35] in intraepithelial lesions and neoplasia of the uterine cervix. Pathologica 2000;92:512-23
7. Munoz M, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl J Med 2003;348:518-27
8. Wieland U, Pfister H. Human papilloma virus infection: a clinical atlas. Ullstein Mosby 1997:1-18
9. Von Krogh G, Lacey CGN, Gross G, et al. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000;76:162-8
10. Liaw K-L, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-60
11. Isacson C, Kelsis TD, Hedrick L, et al. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res 1996;56:669-74
12. Bosch FX, de Sanjosé S. Chapter 1: human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13
13. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8
14. McCrory DC, Matchar DB, Bastian L, et al. Evaluation of cervical cytology. Evidence report/technology assessment. No. 5. (Prepared by Duke University under contract No. 290-97-0014.) AHCPR Publication No. 99-E010. Rockville (MD): Agency for Health Care Policy and Research; February 1999
15. Kahn JA, Millard PJ. Cervical cytology screening and management of abnormal cytology in adolescent girls. J Pediatr Adolesc Gynecol 2003;16:167-71
16. Cervical Screening Programme, England: 2003-2004, Bulletin 2004/20, Government Statistical Service
17. Villa LI, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled mulitcentre phase II efficacy trial. Lancet 2005;6(5):256-7
18. NHS Cevical Cancer Screening Programme, cancerscreening. nhs.uk/cervical/#cost [accessed 4 February 2006]
19. Cervical Screening Wales, Statistical report, cervical screening programme, Wales: 2003-2004; National Assembly for Wales, www.screeningservices.org.uk/cws/results/results.html [accessed 6 February 2006]
20. Scottish Health Statistics, www.isdscotland.org/isd/info3. jsp?pContentID=28878p-applic=ccc&p_service [accessed 6 February 2006]
21. Northern Ireland Statistics and Research Agency, www.dhsspsni. gov.uk/publications/KC53 Report [accessed 4 February 2006]
22. Department of Health, Hospital Episodes Statistics (HES): England, Financial year 2004-04, Government Statistical Service. www.hesonline.nhs.uk [accessed 6 February 2006]
23. Cerri Watts, Health solution Wales, 2005. Personal Communication
24. Laura Kelso, ISD, CSA, Scotland, 2005. IR2005-03308. Inpatient and day cases with primary diagnosis C00-C96. Personal Communication
25. Northern Ireland Statistics and Research Agency, www.dhsspsni. gov.uk/publications/2004 [accessed 4 February 2006]
26. Health Protection Agency, 2003. Supplementary table of sexually transmitted infections in the United Kingdom, www. hpa.org.uk/infections/topics [accessed 4 February 2006]
27. Clinical Effectiveness Group. National guideline for the management of genital warts, BASHH guidelines. 2002
28. Technology assessment report for National Institute for Clinical Excellence. Liquid based cytology in cervical screening: an updated rapid and systematic review. 2003
29. Department of Health. NHS reference costs 2003 and national tariff ('payment by results core tools 2004'). 2004
30. Wolstenholme JL, Whynes DK. Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer 1998;34(12):1889-93
31. The Chartered Institute of Public Finance and Accountancy (CIPFA). The Health Service database 2003 (financial year 2002-2003), CIPFA/HFM, IPF, London
32. Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004;15:501-8
33. Netten A, Dennett J, editors. Unit costs of health and social care 2001. University of Kent at Canterbury: Personal Social Services Research Unit (PSSRU); 2001
34. British National Formulary, www.bnf.org [accessed 4 February 2006]
35. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. J Am Med Assoc 2003;290:781-9
36. Kulasingam SL, Benard S, Barnabas R, Myers ER. Adding a quadrivalent (6, 11, 16 & 18 types) human papillomavirus vaccine to the existing UK cervical screening programme is potentially cost-effective [abstract 0003]. Int J Gynecol Cancer 2005;15:51-80